award

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response

  • Award Number: R01CA255650

  • ORGANIZATION: NATIONAL CANCER INSTITUTE

  • OPDIV: NIH

  • AWARD CLASS: DISCRETIONARY

  • AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

  • PERIOD OF PERFORMANCE START DATE: 08/02/2021

  • PERIOD OF PERFORMANCE END DATE: 07/31/2027